These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Anticalins small engineered binding proteins based on the lipocalin scaffold. Gebauer M; Skerra A Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains. Siegemund M; Oak P; Hansbauer EM; Allersdorfer A; Utschick K; Winter A; Grasmüller C; Galler G; Mayer JP; Weiche B; Prassler J; Kontermann RE; Rothe C Front Pharmacol; 2021; 12():759337. PubMed ID: 34759826 [TBL] [Abstract][Full Text] [Related]
10. Development of a high affinity Anticalin Deuschle FC; Morath V; Schiefner A; Brandt C; Ballke S; Reder S; Steiger K; Schwaiger M; Weber W; Skerra A Theranostics; 2020; 10(5):2172-2187. PubMed ID: 32089738 [TBL] [Abstract][Full Text] [Related]
11. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. Mross K; Richly H; Fischer R; Scharr D; Büchert M; Stern A; Gille H; Audoly LP; Scheulen ME PLoS One; 2013; 8(12):e83232. PubMed ID: 24349470 [TBL] [Abstract][Full Text] [Related]
12. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. Terwisscha van Scheltinga AG; Lub-de Hooge MN; Hinner MJ; Verheijen RB; Allersdorfer A; Hülsmeyer M; Nagengast WB; Schröder CP; Kosterink JG; de Vries EG; Audoly L; Olwill SA J Nucl Med; 2014 Apr; 55(4):665-71. PubMed ID: 24614223 [TBL] [Abstract][Full Text] [Related]
13. Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality. Aubrey N; Gouilleux-Gruart V; Dhommée C; Mariot J; Boursin F; Albrecht N; Bergua C; Croix C; Gilotin M; Haudebourg E; Horiot C; Matthias L; Mouline C; Lajoie L; Munos A; Ferry G; Viaud-Massuard MC; Thibault G; Velge-Roussel F Antibodies (Basel); 2022 Aug; 11(3):. PubMed ID: 35997348 [TBL] [Abstract][Full Text] [Related]
14. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Schlehuber S; Skerra A Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717 [TBL] [Abstract][Full Text] [Related]
15. Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein. Masuda Y; Yamaguchi S; Suzuki C; Aburatani T; Nagano Y; Miyauchi R; Suzuki E; Yamamura N; Nagatomo K; Ishihara H; Okuno K; Nara F; Matschiner G; Hashimoto R; Takahashi T; Nishizawa T J Pharmacol Exp Ther; 2018 May; 365(2):368-378. PubMed ID: 29463608 [TBL] [Abstract][Full Text] [Related]
16. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin. Gebauer M; Schiefner A; Matschiner G; Skerra A J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252 [TBL] [Abstract][Full Text] [Related]
17. Design of a surrogate Anticalin protein directed against CD98hc for preclinical studies in mice. Deuschle FC; Schiefner A; Brandt C; Skerra A Protein Sci; 2020 Aug; 29(8):1774-1783. PubMed ID: 32463547 [TBL] [Abstract][Full Text] [Related]
18. Application of platform process development approaches to the manufacturing of Mabcalin™ bispecifics. Wachter S; Angevin T; Bubna N; Tan A; Cichy A; Brown D; Wolfe LS; Sappington R; Lilla E; Berry L; Grismer D; Orth C; Blanusa M; Mostafa S; Kaufmann H; Felderer K J Biotechnol; 2023 Nov; 377():13-22. PubMed ID: 37820750 [TBL] [Abstract][Full Text] [Related]
19. High-throughput sorting of an Anticalin library via EspP-mediated functional display on the Escherichia coli cell surface. Binder U; Matschiner G; Theobald I; Skerra A J Mol Biol; 2010 Jul; 400(4):783-802. PubMed ID: 20630471 [TBL] [Abstract][Full Text] [Related]